A multicenter prospective observational study on the safety of meglumine gadolinate in the population of Southwest China

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040696

Enrollment

Unknown

Registered

2020-12-08

Start date

2021-03-08

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Safty of Gadoterate meglumine

Interventions

Case series:Gadoterate meglumine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who require contrast-enhanced magnetic resonance (CE-MR) imaging as part of their diagnostic work up

Exclusion criteria

Exclusion criteria: 1. Allergy to Gadolinium contrast medium; 2. Patients who have contraindications of MRI; 3. Having received iodine or gadolinium contrast medium examination within 3 months before current examination; 4. Patients who received contrast media other than meglumine gadolinate during the study period; 5. Patients have participated in another drug/instrument study or undergoing another drug/instrument study; 6. Patients in whom the investigators consider inappropriate to participate in this study,including but not limited to pregnantlactatingalcoholicspsychotic, etc.

Design outcomes

Primary

Measure	Time frame
Adverse events;	—

Countries

China

Contacts

Public ContactChen Tianwu

Affiliated Hospital of North Sichuan Medical College

tianwuchen_nsmc@163.com+86 13990859583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026